2027 ICD-10-CM Diagnosis Code E22.0Acromegaly and pituitary gigantism

ICD-10-CM Codes›E00–E89›E20-E35›E22

ICD-10-CM E22.0
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

E22.0 is a billable ICD-10-CM diagnosis code for acromegaly and pituitary gigantism. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 643 through 645. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Pituitary disorders.

For Medicare Advantage risk adjustment, E22.0 maps to CMS-HCC Category 51 (Addison's and Cushing's Diseases, Acromegaly, and Other Specified Endocrine Disorders) under the V28 model, adding a risk factor of about 0.510 for a community, non-dual, aged beneficiary in payment year 2027.

Code Identity

ICD-10-CM Code
E22.0
Billable Status
Yes — Valid for Submission
Code Describes
Acromegaly and pituitary gigantism
Short Description
Acromegaly and pituitary gigantism
Same as the full description in the CMS dataset.
Parent Code
E22
Hyperfunction of pituitary gland

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE20-E35Disorders of other endocrine glands
CategoryE22Hyperfunction of pituitary gland
This CodeE22.0Acromegaly and pituitary gigantism

Medicare Risk Adjustment (HCC)Billing

E22.0 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.

CMS-HCC V28 Category (Payment Model)
HCC 51— Addison's and Cushing's Diseases, Acromegaly, and Other Specified Endocrine Disorders
Payment HCC · PY 2027 one of 11 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.510
community, non-dual, aged · ranges 0.313–0.654 across segments
Hierarchy
Top of its hierarchy
HCC 51 is not superseded by any other condition category
Prior Model (CMS-HCC V24)
HCC 23
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 23 · ESRD (V21): HCC 23 · ESRD (V24): HCC 23
ESRD V21 weights: 0.013 dialysis, 0.234–0.359 functioning graft · ESRD V24 weights: 0.036 dialysis, 0.217–0.390 functioning graft
Part D (RxHCC)
RxHCC 42 — Acromegaly and Other Endocrine and Metabolic Disorders
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acromegalic cardiomyopathy
  • Acromegalic facies
  • Acromegalic feet
  • Acromegaly
  • Arthropathy associated with acromegaly
  • Endocrine myopathy
  • Eunuchoid gigantism
  • Familial infantile gigantism
  • Gigantism
  • Gigantism and acromegaly
  • Gigantism due to somatostatin deficiency
  • Hyperactive behavior
  • Hypermelanosis due to acromegaly
  • Hypermelanosis due to endocrine disorder
  • Hypersomatotropic gigantism
  • Large, broad feet
  • Myopathy in acromegaly
  • Neuropathy in acromegaly
  • Overproduction of growth hormone
  • Sotos' syndrome
  • X-linked acrogigantism due to Xq26 microduplication
  • X-linked intellectual disability with acromegaly and hyperactivity syndrome

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to E22.0: its own notes plus those printed at E22, block E20-E35, and Chapter 4. A note printed at a category, block or chapter applies to every code under it.

Applicable To

Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.

  • Overproduction of growth hormone

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

On E22.0 itself
  • constitutional gigantism (E34.4)
  • constitutional tall stature (E34.4)
  • increased secretion from endocrine pancreas of growth hormone-releasing hormone (E16.8)
From E22 Hyperfunction of pituitary gland applies to 5 codes
  • Cushing's syndrome (E24.-)
  • Nelson's syndrome (E24.1)
  • overproduction of ACTH not associated with Cushing's disease (E27.0)
  • overproduction of pituitary ACTH (E24.0)
  • overproduction of thyroid-stimulating hormone (E05.8-)
From Block E20-E35 Disorders of other endocrine glands applies to 99 codes
From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Notes

General instructions on how these codes are used.

From Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases applies to 973 codes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Referenced in Other NotesGuidance

Instructional notes printed at other codes that name E22.0, its category, or a range that includes it.

Excludes1 1

These codes carry an Excludes1 note naming E22.0: they are not reported together with it, unless the two conditions are unrelated.

  • M26.0 Major anomalies of jaw size
    acromegaly (E22.0)

Code First 1

These codes say to code first a condition named in the note, and E22.0 is one of the conditions named.

  • G63 Polyneuropathy in diseases classified elsewhere
    endocrine disease, except diabetes (E00-E07, E15-E16, E20-E34) names E20-E34, which includes this code

Notes 1

These notes mention E22.0.

  • Chapter 4 (E00-E89) Endocrine, nutritional and metabolic diseases
    All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere. names E16-E31, which includes this code

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END013
Pituitary disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Acromegaly

    a condition caused by prolonged exposure to excessive human growth hormone in adults. it is characterized by bony enlargement of the face; lower jaw (prognathism); hands; feet; head; and thorax. the most common etiology is a growth hormone-secreting pituitary adenoma. (from joynt, clinical neurology, 1992, ch36, pp79-80)

  • Gigantism

    the condition of accelerated and excessive growth in children or adolescents who are exposed to excess human growth hormone before the closure of epiphyses. it is usually caused by somatotroph hyperplasia or a growth hormone-secreting pituitary adenoma. these patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.

Patient EducationClinical

Pituitary Disorders

Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert E22.0 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
253.0 Acromegaly and gigantism
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About E22.0Overview

What is the ICD-10 code for acromegaly and pituitary gigantism?

The ICD-10-CM code for acromegaly and pituitary gigantism is E22.0 (sometimes written as E220). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

Is E22.0 (Hyperfunction of pituitary gland) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report acromegaly and pituitary gigantism on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What MS-DRG does E22.0 group to?

When acromegaly and pituitary gigantism is the principal diagnosis on an inpatient stay, it groups to MS-DRG 644, 645, 643, with relative weights from 0.7461 to 1.6138 depending on complications. Higher weights mean higher Medicare reimbursement.

Can E22.0 be reported with E34.4?

Not as a rule. The Excludes1 note on E22.0 lists "constitutional gigantism (E34.4)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).

What is the ICD-9 equivalent of E22.0?

Under the General Equivalence Mappings, acromegaly and pituitary gigantism converts to ICD-9-CM 253.0 (acromegaly and gigantism). The mapping is approximate, so confirm the match fits the documentation.

What HCC is E22.0?

E22.0 (acromegaly and pituitary gigantism) maps to CMS-HCC Category 51 (Addison's and Cushing's Diseases, Acromegaly, and Other Specified Endocrine Disorders), commonly written as HCC 51, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 23 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 42.

Does E22.0 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, E22.0 adds a risk adjustment factor of about 0.510 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.313 to 0.654 depending on the payment segment). HCC 51 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 51 category page.